Tremelimumab clinical trials
Also written CP-675,206, Ticilimumab, CP-675206 and Imjudo.
ClinicalTrials.gov finds 278 studies for tremelimumab. How that becomes 221 here
Every study that search finds has been read, to see whether and how it gives tremelimumab. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count
- 278Found by its intervention search · See all 278 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 244 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −3
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerNCT02489448 · Named by mistake among durvalumab's other namesReport a problem
- An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant MelanomasNCT05928962 · Named as a PD-1 antibody; the drug given is unclearReport a problem
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular CancerNCT07226063 · Given before entry; not part of study treatmentReport a problem
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 276Give tremelimumab to participants
- −15Observe patients on it, or give it outside a trial
- −1Compare another treatment with it
- −39Give it beside what is tested
- 221Test it: the count on this site
Get an email when these change. Save the tremelimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Oct 2022 · IMJUDO · BLA 761289 (FDA, Drugs@FDA)
- European Union
- 20 Feb 2023 · Tremelimumab AstraZeneca · EMEA/H/C/004650 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
221 studies that test it; most in 2017 (37)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 6 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 15 |
| 2016 | 27 |
| 2017 | 37 |
| 2018 | 35 |
| 2019 | 16 |
| 2020 | 12 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 11 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 51 · Other 170
AstraZeneca (41) · M.D. Anderson Cancer Center (10) · MedImmune LLC (8) · Canadian Cancer Trials Group (8) · Memorial Sloan Kettering Cancer Center (7) · National Cancer Institute (NCI) (5) · Jonsson Comprehensive Cancer Center (4) · Seoul National University Hospital (4)
Often tested with
Tested in the same studies.
Durvalumab (122) · Durvalumab/Tremelimumab Regimen (6) · Cisplatin (6) · Carboplatin (5) · Olaparib (5) · Bevacizumab (4) · Paclitaxel (4) · Lenvatinib (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Tremelimumab is the comparator. A study of two new drugs counts under both.
- 1Livmoniplimab · AbbVie · next primary completion Jan 2027
- 1Budigalimab · AbbVie · next primary completion Jan 2027
New treatments tested with it · 8 most studied
New when their studies opened, with tremelimumab beside them; studies of each.
Reaching primary completion within a year · 24, 2 in phase 3
Studies that test tremelimumab, phase 3 first.
- Dec 2026Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCPhase 3 · Stanford University
- Oct 2027Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.Phase 3 · Hamilton Health Sciences Corporation
- Nov 2026Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2026Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Nov 2026Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerPhase 2 · Emory University
- Nov 2026Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaPhase 2 · AstraZeneca
- Nov 2026Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaPhase 1 · Mayo Clinic
- Dec 2026Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLCPhase 2 · ETOP IBCSG Partners Foundation
- Dec 2026Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyPhase 2 · Sheba Medical Center
- Dec 2026Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaPhase 2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses tremelimumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 221
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225With durvalumab and chemotherapy in biliary cancerWritten as TremelimumabReport a problem
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034With durvalumab in one second-line armWritten as TremelimumabReport a problem
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Added to new rilvegostomig and bevacizumab in liver cancerWritten as TremelimumabReport a problem
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for MesotheliomaRecruitingPhase 1/2Baylor College of MedicineNCT05932199With durvalumab, with or without chemotherapy, in mesotheliomaReport a problem
- Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999707With durvalumab and photon radiotherapy in liver cancerWritten as TremelimumabReport a problem
- Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999694With durvalumab and proton radiotherapy in liver cancerWritten as TremelimumabReport a problem
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingPhase 3Stanford UniversityNCT04585490Added when blood DNA shows residual diseaseWritten as TremelimumabReport a problem
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.RecruitingPhase 3Hamilton Health Sciences CorporationNCT07027436With durvalumab after radiation, before surgeryReport a problem
- A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingPhase 2Canadian Cancer Trials GroupNCT03847649Continued with durvalumab for people from earlier trialsWritten as TremelimumabReport a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690One dose before pancreatic surgery, a window armWritten as TremelimumabReport a problem
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001With durvalumab as maintenance in a matched-therapy studyWritten as Durvalumab + TremelimumabReport a problem
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingEarly Phase 1University of California, IrvineNCT06824363One dose with durvalumab before gastro-oesophageal surgeryWritten as TremelimumabReport a problem
- Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingPhase 1Mayo ClinicNCT06058663With durvalumab and radioembolisation in cholangiocarcinomaWritten as TremelimumabReport a problem
- Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingPhase 2Center Eugene MarquisNCT07122089With durvalumab after SIRT in liver cancerWritten as TremelimumabReport a problem
- IIT2025-03-YANG-LIFT-HCCRecruitingPhase 2Ju Dong YangNCT07489976With durvalumab and locoregional therapy in liver cancerReport a problem
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingPhase 2Georgetown UniversityNCT04499053With durvalumab and chemotherapy in people with HIVWritten as TremelimumabReport a problem
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingPhase 2Emory UniversityNCT07174570With durvalumab and celecoxib in liver cancerWritten as TremelimumabReport a problem
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingPhase 1/2Anwaar SaeedNCT03539822Added to cabozantinib and durvalumab in some cohortsWritten as TremelimumabReport a problem
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingPhase 2The University of Texas Health Science Center at San AntonioNCT06526104With durvalumab in liver cancer with Child-Pugh BWritten as TremelimumabReport a problem
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingPhase 2Mary Feng, MDNCT04430452Added to durvalumab after palliative radiotherapy in liver cancerWritten as TremelimumabReport a problem
See all 221 studies that test tremelimumab →
Behind its US label · 2 — the studies the FDA label of IMJUDO describes
From the Clinical Studies section of IMJUDO (2026-08), as openFDA has it. A study the site does not hold is left out.
- Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingPhase 3AstraZenecaNCT03164616Report a problem
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingPhase 3AstraZenecaNCT03298451Report a problem
Tested on its own · 11 — no other medicine in its arm
- Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant MesotheliomaActive, not recruitingPhase 2MedImmune LLCNCT01843374Against placebo in mesotheliomaWritten as TremelimumabReport a problem
- Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial CancerCompletedPhase 2Matthew GalskyNCT03557918Alone in pretreated urothelial cancerWritten as TremelimumabReport a problem
- Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid CarcinomaCompletedPhase 2Seoul National University HospitalNCT06446570With durvalumab in sarcomatoid lung cancerWritten as Durvalumab,TremelimumabReport a problem
- GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCompletedPhase 1/2Asan Medical CenterNCT03751761With durvalumab and paclitaxel in gastric cancerWritten as durvalumab, tremelimumab, paclitaxelReport a problem
- Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingPhase 2Centre Georges Francois LeclercNCT04169841With durvalumab and olaparib in repair-deficient cancersWritten as olaparib, durvalumab, tremelimumabReport a problem
- Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder CancerWithdrawnPhase 1/2University of British ColumbiaNCT05120622Injected into the bladder with durvalumabWritten as TremelimumabReport a problem
- Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney CancerCompletedEarly Phase 1M.D. Anderson Cancer CenterNCT02626130Alone or with cryoablation in kidney cancerWritten as TremelimumabReport a problem
- Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II MelanomaCompletedPhase 1A.J.M. van den EertweghNCT04274816Injected into the skin in early melanomaWritten as TremelimumabReport a problem
- Tremelimumab With Chemoembolization or Ablation for Liver CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01853618With chemoembolisation or ablation in liver cancerWritten as TremelimumabReport a problem
- The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant MesotheliomaStatus unknownPhase 2Azienda Ospedaliera Universitaria SeneseNCT01655888Alone on a denser schedule in mesotheliomaWritten as TremelimumabReport a problem
- A Clinical Study With Tremelimumab as Monotherapy in Malignant MesotheliomaStatus unknownPhase 2Azienda Ospedaliera Universitaria SeneseNCT01649024Alone in mesotheliomaWritten as TremelimumabReport a problem
Tested with established drugs · 66 — they are given beside it
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung CancerRecruitingPhase 2Georgetown UniversityNCT04499053With durvalumab and chemotherapy in people with HIVWritten as TremelimumabReport a problem
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04034927Added to olaparib in ovarian cancerWritten as TremelimumabReport a problem
- Durvalumab and Tremelimumab for Pediatric MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT03837899With durvalumab in children's cancers, doses foundWritten as Durvalumab / Tremelimumab Combination TherapyReport a problem
- TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingPhase 2The University of Hong KongNCT04988945With durvalumab after TACE and SBRT in liver cancerWritten as TremelimumabReport a problem
- Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03158064With durvalumab in germ cell tumoursWritten as TremelimumabReport a problem
- TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingPhase 2Gruppo Oncologico del Nord-OvestNCT04817826With durvalumab before or instead of surgery in MSI gastric cancerWritten as TremelimumabReport a problem
- Immunotherapy and SBRT for Metastatic Head and Neck CarcinomasCompletedPhase 1/2Centre hospitalier de l'Université de Montréal (CHUM)NCT03283605With durvalumab and SBRT in head and neck cancerWritten as TremelimumabReport a problem
- Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT03026062With durvalumab, in sequence or together, in ovarian cancerWritten as TremelimumabReport a problem
- Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCCActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT04522544With durvalumab and SIRT or TACE in liver cancerWritten as TremelimumabReport a problem
- Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver TransplantTerminatedPhase 2University of CincinnatiNCT05027425With durvalumab before liver transplantWritten as TremelimumabReport a problem
- Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerActive, not recruitingPhase 2Massachusetts General HospitalNCT03482102With durvalumab and radiotherapy in liver and biliary cancerWritten as TremelimumabReport a problem
- Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver CancerActive, not recruitingPhase 1City of Hope Medical CenterNCT04605731With durvalumab after radioembolisation in liver cancerWritten as TremelimumabReport a problem
- Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY TrialTerminatedPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT03753919With durvalumab in thyroid cancerWritten as TremelimumabReport a problem
- CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03638141With durvalumab after TACE in liver cancerWritten as TremelimumabReport a problem
- Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active, not recruitingPhase 2GERCOR - Multidisciplinary Oncology Cooperative GroupNCT03704480With durvalumab, with or without paclitaxel, in biliary cancerWritten as TremelimumabReport a problem
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedPhase 1Dana-Farber Cancer InstituteNCT03277482With durvalumab and radiotherapy in gynaecological cancerWritten as TremelimumabReport a problem
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingPhase 1/2New Mexico Cancer Research AllianceNCT02571725With olaparib in BRCA ovarian cancerWritten as TremelimumabReport a problem
- A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerCompletedPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT03212469With durvalumab and SBRT in metastatic cancerWritten as TremelimumabReport a problem
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedPhase 1/2The Netherlands Cancer InstituteNCT03871036Alone or with durvalumab, doses found, in bladder cancerWritten as TremelimumabReport a problem
- Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive, not recruitingPhase 2Sheba Medical CenterNCT05000710With durvalumab and radiotherapy after first-line immunotherapyWritten as TremelimumabReport a problem
Showing 20 of 66. See all 66 →
Tested in a combination · 143 — another drug in the study is under test too
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225With durvalumab and chemotherapy in biliary cancerWritten as TremelimumabReport a problem
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034With durvalumab in one second-line armWritten as TremelimumabReport a problem
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Added to new rilvegostomig and bevacizumab in liver cancerWritten as TremelimumabReport a problem
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for MesotheliomaRecruitingPhase 1/2Baylor College of MedicineNCT05932199With durvalumab, with or without chemotherapy, in mesotheliomaReport a problem
- Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999707With durvalumab and photon radiotherapy in liver cancerWritten as TremelimumabReport a problem
- Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCCRecruitingPhase 2Chang Gung Memorial HospitalNCT06999694With durvalumab and proton radiotherapy in liver cancerWritten as TremelimumabReport a problem
- Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCRecruitingPhase 3Stanford UniversityNCT04585490Added when blood DNA shows residual diseaseWritten as TremelimumabReport a problem
- Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.RecruitingPhase 3Hamilton Health Sciences CorporationNCT07027436With durvalumab after radiation, before surgeryReport a problem
- A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruitingPhase 2Canadian Cancer Trials GroupNCT03847649Continued with durvalumab for people from earlier trialsWritten as TremelimumabReport a problem
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingEarly Phase 1OHSU Knight Cancer InstituteNCT04005690One dose before pancreatic surgery, a window armWritten as TremelimumabReport a problem
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001With durvalumab as maintenance in a matched-therapy studyWritten as Durvalumab + TremelimumabReport a problem
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a MuRecruitingEarly Phase 1University of California, IrvineNCT06824363One dose with durvalumab before gastro-oesophageal surgeryWritten as TremelimumabReport a problem
- Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingPhase 1Mayo ClinicNCT06058663With durvalumab and radioembolisation in cholangiocarcinomaWritten as TremelimumabReport a problem
- Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein ThrombosisRecruitingPhase 2Center Eugene MarquisNCT07122089With durvalumab after SIRT in liver cancerWritten as TremelimumabReport a problem
- IIT2025-03-YANG-LIFT-HCCRecruitingPhase 2Ju Dong YangNCT07489976With durvalumab and locoregional therapy in liver cancerReport a problem
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerRecruitingPhase 2Emory UniversityNCT07174570With durvalumab and celecoxib in liver cancerWritten as TremelimumabReport a problem
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingPhase 1/2Anwaar SaeedNCT03539822Added to cabozantinib and durvalumab in some cohortsWritten as TremelimumabReport a problem
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B CirrhosisRecruitingPhase 2The University of Texas Health Science Center at San AntonioNCT06526104With durvalumab in liver cancer with Child-Pugh BWritten as TremelimumabReport a problem
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingPhase 2Mary Feng, MDNCT04430452Added to durvalumab after palliative radiotherapy in liver cancerWritten as TremelimumabReport a problem
- Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular CarcinomaRecruitingPhase 1/2Yoon Jun KimNCT06911255With durvalumab and TACE in liver cancerReport a problem
Showing 20 of 143. See all 143 →
Beside an established treatment under test · 16 — an approved drug, surgery or radiation is what the study tests
Tested with tremelimumab: Radiation 5 · Surgery or a procedure 2 · belinostat 1 · Cyclophosphamide 1 · Capecitabine 1 · Durvalumab/Tremelimumab Regimen 1 · Semaglutide 1 · Systemic Therapy 1
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerRecruitingEarly Phase 1University of ArizonaNCT07627191Standard treatment with durvalumab; semaglutide is addedReport a problem
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06840782One standard option; local ablative treatment is addedReport a problem
- Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic TreatmentNot yet recruitingPhase 2Chang Gung Memorial HospitalNCT07168668One systemic option; partial TACE is addedReport a problem
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingPhase 2Samsung Medical CenterNCT07884877One systemic option; PULSAR radiotherapy is addedReport a problem
- Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingPhase 3Shandong Cancer Hospital and InstituteNCT06841172One of many systemic options; radiotherapy is studiedReport a problem
- A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingPhase 1AstraZenecaNCT07391670In every armGiven with durvalumab in some cohorts; durvalumab's route is studiedWritten as TremelimumabReport a problem
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406In every armOne checkpoint option; SBRT is addedWritten as TremelimumabReport a problem
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06880523Both arms take it with durvalumab; lenvatinib is addedReport a problem
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingPhase 2Northwestern UniversityNCT05620771Alternative to atezolizumab-bevacizumab with Y-90Report a problem
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingPhase 2/3UNICANCERNCT06904170In every armBoth arms take it with durvalumab; HAIC is addedWritten as Durvalumab Plus TremelimumabReport a problem
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02888743In every armEvery arm takes it with durvalumab; radiotherapy is addedWritten as TremelimumabReport a problem
- Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedPhase 1University of UtahNCT05154994Fixed partner while belinostat's dose is foundReport a problem
- Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLCActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT03057106In every armBoth arms take it with durvalumab; chemotherapy is addedWritten as TremelimumabReport a problem
- ......SMARTEST Trial......CompletedPhase 2University Health Network, TorontoNCT05380713In every armConsolidation with durvalumab after surgery; cyclophosphamide is studiedWritten as TremelimumabReport a problem
- Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer PatientsCompletedPhase 1Massachusetts General HospitalNCT03019003Partner of azacitidine after checkpoint failureWritten as TremelimumabReport a problem
- Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract CancerCompletedPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT05239169In every armEvery arm takes it with durvalumab; capecitabine is addedWritten as TremelimumabReport a problem
Beside a new treatment under test · 23 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with tremelimumab: durvalumab 3 · zanzalintinib 2 · nelitolimod 1 · danvatirsen 1 · azd-5069 1 · feladilimab 1 · JX-594 1 · MEDI3617 1
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingPhase 2Anwaar SaeedNCT06698250In every armPartner of new zanzalintinibWritten as TremelimumabReport a problem
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967In every armEvery arm takes it; a new vaccine is addedWritten as TremelimumabReport a problem
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06564623In every armPartner of a new peptide vaccineWritten as TremelimumabReport a problem
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRecruitingPhase 2Riboscience, LLC.NCT07175441Partner of new RBS2418Report a problem
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2OHSU Knight Cancer InstituteNCT07511504In every armPartner of new zanzalintinib with Y-90Written as TremelimumabReport a problem
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingPhase 1University of California, San DiegoNCT06710223In every armPartner of new SD-101 after cryoablationWritten as TremelimumabReport a problem
- BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular CarcinomaWithdrawnPhase 1/2Case Comprehensive Cancer CenterNCT06608940In every armPartner of new BC3402Written as TremelimumabReport a problem
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedPhase 1/2AstraZenecaNCT02499328Partner of new danvatirsen or AZD5069 in some armsWritten as tremelimumab (treme)Report a problem
- Trial in Patients With Relapsed Ovarian CancerCompletedPhase 2Nordic Society of Gynaecological Oncology - Clinical Trials UnitNCT03267589Partner of new MEDI0562 in one cohortReport a problem
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedPhase 1/2GlaxoSmithKlineNCT03693612Partner of new feladilimabWritten as TremelimumabReport a problem
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawnPhase 1/2Immunocore LtdNCT02535078Partner of new tebentafusp in some armsReport a problem
- Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedPhase 1Kyowa Kirin, Inc.NCT02301130Partner of mogamulizumab, whose dose is foundWritten as tremelimumabReport a problem
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)TerminatedPhase 1PfizerNCT02616185In every armPart of a new vaccine-based regimen in prostate cancerWritten as TremelimumabReport a problem
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT03206073Partner of new Pexa-Vec virus in some armsWritten as TremelimumabReport a problem
- A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02718911Partner of new LY3022855Written as TremelimumabReport a problem
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV MelanomaCompletedPhase 1F. Stephen Hodi, MDNCT02141542In every armFixed partner while new MEDI3617's dose is foundWritten as TremelimumabReport a problem
- Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCCompletedPhase 1/2Ludwig Institute for Cancer ResearchNCT03164772Partner of new mRNA vaccineWritten as TremelimumabReport a problem
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnEarly Phase 1Yale UniversityNCT04223648In every armOne of the checkpoint pairs used to mobilise T cellsWritten as tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapyReport a problem
- MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedPhase 1MedImmune LLCNCT03089645Partner of new MEDI5083 in some partsReport a problem
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedPhase 1AstraZenecaNCT02586987Partner of selumetinib, whose dose is escalatedWritten as TremelimumabReport a problem
Showing 20 of 23. See all 23 →
As the comparator · 1 — what is tested is compared with tremelimumab
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272The comparator for new livmoniplimab with budigalimabWritten as TremelimumabReport a problem
Observed · 15 — patients on it are followed, or it is given outside a trial
- Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingAssiut UniversityNCT07904494Observed with durvalumab in liver cancer in EgyptWritten as Durvalumab Plus TremelimumabReport a problem
- Observational Study Protocol: LIVER-RRecruitingAstraZenecaNCT06252753Real-world outcomes of durvalumab regimens including itReport a problem
- MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.RecruitingAstraZenecaNCT07607769With durvalumab, liver function and quality of life observedReport a problem
- NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic AlterationsRecruitingAstraZenecaNCT06494540With durvalumab and chemotherapy in practiceReport a problem
- Real-world Insight Into Systemic Therapies for HCC: Single-center StudyRecruitingMansoura UniversityNCT07814014Among real-world liver cancer treatmentsReport a problem
- Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and DurvalumabRecruitingNot applicableCentre Hospitalier Universitaire de BesanconNCT06796114Given as care; outcome biomarkers studiedReport a problem
- Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular CarcinomaRecruitingIRCCS Azienda Ospedaliero-Universitaria di BolognaNCT06806579Among liver cancer immunotherapies in practiceReport a problem
- Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingCCTU- Cancer ThemeNCT04107168Among immunotherapy drugs, gut microbiome studiedWritten as TremelimumabReport a problem
- An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With SurgeryActive, not recruitingBayerNCT06117891Observed with durvalumab after earlier liver cancer treatmentWritten as Tremelimumab,Report a problem
- Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in SohagActive, not recruitingSohag Oncology CenterNCT07669597With durvalumab against atezolizumab-bevacizumab, retrospectiveReport a problem
- EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance DatabaseCompletedGroupe Hospitalier Pitie-SalpetriereNCT05934214Among checkpoint drugs, side effects in a global databaseReport a problem
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedSWOG Cancer Research NetworkNCT02154490Observed in a lung cancer screening study's sub-studiesWritten as TremelimumabReport a problem
- Himalaya Early Access ProgramApproved for marketingAstraZenecaNCT05345678Early access with durvalumab in liver cancerWritten as TremelimumabReport a problem
- Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn DiseaseTerminatedVanderbilt-Ingram Cancer CenterNCT00897312Biomarkers in blood observed during biological therapyWritten as ticilimumabReport a problem
- Treatment Use Study for Advanced Melanoma.No longer availablePfizerNCT00584493Treatment access in advanced melanoma before approvalWritten as CP-675,206Report a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue SarcomaNov 5, 2026NCT03116529
Codes
What other systems call tremelimumab · ClinicalTrials.gg INT005105
- MeSH (NLM) C520704tremelimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) QEN1X95CIXTREMELIMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2619313One source FDA
- Wikidata Q7838098tremelimumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49085TremelimumabOne source FDA
- DrugBank DB11771One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520704 | tremelimumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | QEN1X95CIX | TREMELIMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2619313 | — | One source FDA |
| Wikidata | Q7838098 | tremelimumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49085 | Tremelimumab | One source FDA |
| DrugBank | DB11771 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.